Evidence map›Paper›PMID 42534800›Full record

ArticleFrontiers in immunology2026

Bacillus Calmette-Guérin as adjuvant platform enhances immunogenicity of conserved epitopes from structural proteins of SARS-CoV-2.

Ana de Souza Santos, Leonardo Pereira de Araújo, Diego Jose Belato Orts, Hernan Hermes Monteiro da Costa, Kely Catarine Matteucci, Evandro Neves Silva, Karen Cristina Oliveira, Giovane Galdino, Carlos Roberto Prudencio, Patrícia Paiva Corsetti and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Ana de Souza SantosLaboratory of Molecular Biology of Microorganisms, Federal University of Alfenas (UNIFAL-MG), Alfenas, MG, Brazil.
Leonardo Pereira de AraújoLaboratory of Molecular Biology of Microorganisms, Federal University of Alfenas (UNIFAL-MG), Alfenas, MG, Brazil.
Diego Jose Belato OrtsLaboratory of Immunotechnology, Center of Immunology, Institute Adolfo Lutz, São Paulo, SP, Brazil.
Hernan Hermes Monteiro da CostaLaboratory of Immunotechnology, Center of Immunology, Institute Adolfo Lutz, São Paulo, SP, Brazil.
Kely Catarine MatteucciDepartment of Biochemistry and Immunology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP, Brazil.
Evandro Neves SilvaLaboratory of Molecular Biology of Microorganisms, Federal University of Alfenas (UNIFAL-MG), Alfenas, MG, Brazil.
Karen Cristina OliveiraLaboratory of Molecular Biology of Microorganisms, Federal University of Alfenas (UNIFAL-MG), Alfenas, MG, Brazil.
Giovane GaldinoMultipurpose Laboratory, Butantan Institute, São Paulo, SP, Brazil.
Carlos Roberto PrudencioLaboratory of Immunotechnology, Center of Immunology, Institute Adolfo Lutz, São Paulo, SP, Brazil.
Patrícia Paiva CorsettiLaboratory of Molecular Biology of Microorganisms, Federal University of Alfenas (UNIFAL-MG), Alfenas, MG, Brazil.
Leonardo Augusto de AlmeidaLaboratory of Molecular Biology of Microorganisms, Federal University of Alfenas (UNIFAL-MG), Alfenas, MG, Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The development of effective and broadly protective vaccines against SARS-CoV-2 remains a global priority. Conserved epitopes from viral structural proteins (E, M, N, and S) represent promising targets less affected by emerging mutations, while

Indexed as

Adjuvants, ImmunologicBCG VaccineCOVID-19COVID-19 VaccinesEpitopesSARS-CoV-2Viral Structural ProteinsAnimalsAntibodies, ViralCytokinesFemaleHumansImmunogenicity, VaccineMiceMice, Inbred BALB CProtein Subunit VaccinesAdjuvants, ImmunologicAntibodies, ViralBCG VaccineCOVID-19 VaccinesCytokinesEpitopesProtein Subunit VaccinesViral Structural ProteinsBCG vaccineconserved epitopesmulti-epitope vaccineSARS-CoV-2trained immunity

Identifiers

PMID42534800
PMCPMC13422184

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.